Your search returned over 250 studies. The top 250 studies are being displayed. Please use additional keywords or decrease the search distance. Get alerts for new studies
- Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
Conditions: Schizophrenia
Location: Norwalk, California
- Study of the Contraceptive Efficacy and Safety of Amphora Gel Compared to Conceptrol Vaginal Gel
Conditions: Contraception
Location: Denver, Colorado
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Bloomington, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Bloomington%, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Eureka, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Eureka, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Normal, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Normal, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Normal, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Ottawa, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Ottawa, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Bloomington, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Eureka, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Normal, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Normal, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Ottawa, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Urbana, Illinois
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Kankakee, Illinois
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Urbana, Illinois
- Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metas
Conditions: Metastatic Cancer - Prostate Cancer
Location: Kankakee, Illinois
- Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metas
Conditions: Metastatic Cancer - Prostate Cancer
Location: Urbana, Illinois
- Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metas
Conditions: Metastatic Cancer - Prostate Cancer
Location: Urbana, Illinois
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Urbana, Illinois
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma
Location: Kankakee, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Bloomington%, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Eureka, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Eureka, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Normal, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Normal, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Normal, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Ottawa, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Ottawa, Illinois
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Leukemia
Location: Kankakee, Illinois
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Location: Kankakee, Illinois
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Location: Urbana, Illinois
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Location: Urbana, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Bloomington%, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Eureka, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Eureka, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Normal, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Normal, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Normal, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Ottawa, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Ottawa, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Bloomington, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Bloomington%, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Eureka, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Eureka, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Normal, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Normal, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Normal, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Ottawa, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Ottawa, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Urbana, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Bloomington, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Eureka, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Normal, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Normal, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Ottawa, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Ottawa, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Urbana, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Urbana, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Bloomington, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Bloomington%, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Eureka, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Eureka, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Normal, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Normal, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Normal, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Ottawa, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Ottawa, Illinois
- Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Conditions: Leukemia
Location: Kankakee, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Bloomington, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Bloomington%, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Eureka, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Eureka, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Normal, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Normal, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Normal, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Ottawa, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Ottawa, Illinois
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Urbana, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Bloomington, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Bloomington%, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Eureka, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Eureka, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Kankakee, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Normal, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Normal, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Normal, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Ottawa, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Ottawa, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Urbana, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Bloomington%, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Eureka, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Eureka, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Kankakee, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Normal, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Normal, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Normal, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Ottawa, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Ottawa, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Urbana, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Bloomington%, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Eureka, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Eureka, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottawa, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottawa, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Urbana, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Bloomington%, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Eureka, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Eureka, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Kankakee, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottawa, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottawa, Illinois
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Kankakee, Illinois
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Urbana, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Bloomington%, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Eureka, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Eureka, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Kankakee, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Normal, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Normal, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Normal, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Ottawa, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Ottawa, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Urbana, Illinois
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia - Leukemia - Myelodysplastic Syndromes
Location: Kankakee, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Bloomington, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Bloomington%, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Eureka, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Eureka, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Normal, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Normal, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Normal, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Ottawa, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Ottawa, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Urbana, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Bloomington, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Bloomington%, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Eureka, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Eureka, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Normal, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Normal, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Normal, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Ottawa, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Ottawa, Illinois
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Eureka, Illinois
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Normal, Illinois
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Normal, Illinois
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Ottawa, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Bloomington, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Bloomington%, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Eureka, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Eureka, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Normal, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Normal, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Normal, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Ottawa, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Ottawa, Illinois
- Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
Conditions: Asthma
Location: Normal, Illinois
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Bloomington, Illinois
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Bloomington%, Illinois
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Eureka, Illinois
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Eureka, Illinois
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Kankakee, Illinois
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Normal, Illinois
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Normal, Illinois
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Normal, Illinois
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Ottawa, Illinois
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Ottawa, Illinois
- Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Kankakee, Illinois
- Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Urbana, Illinois
- Vascular and Neuro-inflammatory Effects of Endurance Exercise Training in African Americans
Conditions: Vascular Health - Autonomic Function
Location: Urbana, Illinois
- Activity, Gait, and Efficacy (AGE II): Functional Limitations and Quality of Life
Conditions: Aging
Location: Urbana, Illinois
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Bloomington, Illinois
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Eureka, Illinois
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottawa, Illinois
- Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Bloomington, Illinois
- Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Bloomington%, Illinois
- Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Eureka, Illinois
- Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Eureka, Illinois
- Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottawa, Illinois
- Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottawa, Illinois
- Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Canc
Conditions: Adenocarcinoma of the Gastroesophageal Junction - Esophageal Cancer
Location: Bloomington, Illinois
- Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Canc
Conditions: Adenocarcinoma of the Gastroesophageal Junction - Esophageal Cancer
Location: Eureka, Illinois
- Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Canc
Conditions: Adenocarcinoma of the Gastroesophageal Junction - Esophageal Cancer
Location: Kankakee, Illinois
- Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Canc
Conditions: Adenocarcinoma of the Gastroesophageal Junction - Esophageal Cancer
Location: Normal, Illinois
- Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Canc
Conditions: Adenocarcinoma of the Gastroesophageal Junction - Esophageal Cancer
Location: Normal, Illinois
- Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Canc
Conditions: Adenocarcinoma of the Gastroesophageal Junction - Esophageal Cancer
Location: Ottawa, Illinois
- Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Prostate Cancer
Location: Kankakee, Illinois
- HOME Study: Hysteroscopic Office Myomectomy Evaluation
Conditions: Uterine Fibroids - Polyps
Location: Champaign, Illinois
- Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Conditions: Kidney Cancer
Location: Bloomington, Illinois
- Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Conditions: Kidney Cancer
Location: Eureka, Illinois
- Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Conditions: Kidney Cancer
Location: Kankakee, Illinois
- Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Conditions: Kidney Cancer
Location: Normal, Illinois
- Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Conditions: Kidney Cancer
Location: Normal, Illinois
- Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Conditions: Kidney Cancer
Location: Ottawa, Illinois
- Intra Hemodialytic Oral Protein and Exercise (IHOPE)
Conditions: Kidney Diseases
Location: Urbana, Illinois
- Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting
Conditions: Cardiovascular Disease Risk - Vascular Function - Hemostatic Function
Location: Champaign, Illinois
- Effects of Pomegranate Supplementation on Physical Function and Cardiovascular Disease Risk in Chronic Kidney Disease Patients
Conditions: Chronic Kidney Disease - Cardiovascular Disease
Location: Champaign, Illinois
- Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Can
Conditions: Colorectal Cancer
Location: Bloomington, Illinois
- Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Can
Conditions: Colorectal Cancer
Location: Morris, Illinois
- Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Can
Conditions: Colorectal Cancer
Location: Ottawa, Illinois
- Evaluation of the Performance of Two Contact Lenses Compared to a Marketed Lens
Conditions: Myopia
Location: Bloomington, Illinois
- Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
Conditions: Breast Cancer
Location: Bloomington%, Illinois
- Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
Conditions: Breast Cancer
Location: Eureka, Illinois
- Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
Conditions: Breast Cancer
Location: Normal, Illinois
- Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
Conditions: Breast Cancer
Location: Normal, Illinois
- Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
Conditions: Breast Cancer
Location: Ottawa, Illinois
- Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
Conditions: Bladder Cancer
Location: Normal, Illinois
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
Conditions: Prostate Cancer
Location: Urbana, Illinois
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Tri
Conditions: Breast Cancer
Location: Normal, Illinois
- Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer
Conditions: Anal Cancer
Location: Kankakee, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Bloomington, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Bloomington%, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Eureka, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Eureka, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Kankakee, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Normal, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Normal, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Normal, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Normal, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Ottawa, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Ottawa, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Urbana, Illinois
- A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis
Conditions: Atopic Dermatitis
Location: Champaign, Illinois
- Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Conditions: Crohn's Disease
Location: Urbana, Illinois
- Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Conditions: Endometrial Cancer
Location: Bloomington, Illinois
- Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Conditions: Endometrial Cancer
Location: Normal, Illinois
- Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Conditions: Endometrial Cancer
Location: Normal, Illinois
- Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Conditions: Endometrial Cancer
Location: Ottawa, Illinois
- Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Conditions: Endometrial Cancer
Location: Ottawa, Illinois
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Leukemia
Location: Kankakee, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Bloomington, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Bloomington%, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Eureka, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Eureka, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Kankakee, Illinois
|